Novavax Inc. ($NVAX) Stock Forecast: Down 11.2% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing vaccines for a range of infectious diseases. The stock is listed on the NASDAQ exchange.

Why is Novavax Inc. going down?

NVAX stock is down 11.2% on Jan 9, 2025 20:05

• Novavax (NVAX) witnessed a significant 11.2% decrease in its shares amid a strong bearish movement today.
• Investor sentiment turned negative due to reports of the first human death in the U.S. linked to the H5N1 bird flu virus and information from a major health organization about the rise in respiratory illnesses. This caused volatility in the vaccine stock sector.
• While there was a noteworthy 13.5% surge in the share price recently following reports of a sharp uptick in respiratory illnesses by the aforementioned health organization, apprehensions stemming from the bird flu fatality dampened overall investor confidence, leading to the bearish sentiment.
• The conflicting information and uncertainties surrounding respiratory illnesses, as well as the progress in vaccine development, likely contributed to the stock's erratic performance and subsequent decline.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Why Novavax ( NVAX ) Stock Is Volatile This Week - Novavax ( NASDAQ:NVAX )

Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses. Get New Picks of the Market's Top Stocks Novavax Inc NVAX shares dipped 11.2% to $9.60 during Wednesday's session, pulling back ...

https://www.benzinga.com/news/25/01/42901509/why-novavax-nvax-stock-is-volatile-this-week

Strength Seen in Novavax ( NVAX ) : Can Its 10.9% Jump Turn into More Strength?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2393409/strength-seen-in-novavax-nvax-can-its-109-jump-turn-into-more-strength

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally - Novavax ( NASDAQ:NVAX )

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses nationwide.

https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally

Why Novavax ( NVAX ) Stock Is Rising - Novavax ( NASDAQ:NVAX )

Novavax shares are trading higher by 13.5% during Tuesday's session. A recent CDC report highlights a sharp increase in respiratory illnesses across the United States.

https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising

Trending Today

Cardano ($ADA) Crypto Forecast: Down 5.3% Today

Movement ($MOVE) Crypto Forecast: Down 5.3% Today

Aave ($AAVE) Crypto Forecast: Down 5.5% Today

Curve DAO Token ($CRV) Crypto Forecast: Down 5.1% Today

Bitcoin SV ($BSV) Crypto Forecast: Up 14.3% Today

Pendle ($PENDLE) Crypto Forecast: Down 5.6% Today

Ethena ($ENA) Crypto Forecast: Down 6.7% Today

Jito ($JTO) Crypto Forecast: Down 5.2% Today

Fantom ($FTM) Crypto Forecast: Up 6.7% Today

EigenLayer ($EIGEN) Crypto Forecast: Down 5.2% Today

Novavax Inc. Price History

07.00.2025 - NVAX Stock was up 12.2%

• NVAX stock experienced a strong bullish movement following reports of the first human death in the U.S. related to the H5N1 bird flu virus and high levels of respiratory illnesses nationwide.
• The sharp increase in respiratory illnesses highlighted in a recent CDC report has led to increased investor interest in Novavax's vaccine development efforts.
• The market movement reflects the growing demand for vaccines and medical solutions in response to public health concerns, driving up NVAX stock prices significantly.

07.00.2025 - NVAX Stock was up 15.2%

• NVAX stock increased by 13.5%.
• The rise in respiratory illnesses in the United States possibly boosted investor confidence in Novavax's vaccine development.
• Positive updates on the effectiveness of Novavax's vaccines in treating respiratory illnesses influenced the bullish movement in NVAX stock.

15.10.2024 - NVAX Stock was down 10.4%

• NVAX displayed a downward trend in trading today.
• The market's response was adverse following the announcement of Robert F. Kennedy Jr., known for his skepticism towards vaccines, being appointed to lead the HHS, leading to a decline in vaccine-related stocks.
• Although NVAX posted better-than-expected earnings and revenue for Q3, the stock price dropped as company officials revised their sales forecast downwards, citing reduced uptake of the COVID-19 vaccine.
• Despite the recent decline, a notable uptick in options trading favoring NVAX suggests continued positive investor sentiment for the company's long-term outlook.

06.11.2024 - NVAX Stock was up 10.0%

• Novavax (NVAX) saw a significant increase in its stock price after announcing the sale of its Czech manufacturing facility to Novo Nordisk for $200 million.
• The sale is anticipated to provide Novavax with additional funds to enhance its vaccine pipeline, likely boosting investor confidence in the company's future prospects.
• This strategic decision not only infuses capital into Novavax but also enables them to streamline operations and concentrate on their core expertise of vaccine development, potentially resulting in sustained growth and advancements in the industry.

12.11.2024 - NVAX Stock was up 5.1%

• NVAX stock surged as the company announced the start of a late-stage study on COVID-19-flu combination and standalone flu vaccines, indicating progress in its vaccine development efforts.
• The FDA granting Fast Track designation to Sanofi's vaccine candidates for COVID-19 and influenza may have positively impacted NVAX, as it highlights the importance and potential demand for such vaccines.
• Despite some negative sentiment from Jim Cramer, the news of Novavax selling its manufacturing plant for $200 million to Novo Nordisk could be seen as a strategic move to streamline operations and focus on vaccine development, which investors may have viewed favorably.
• Overall, the bullish movement in NVAX could be attributed to positive developments in its vaccine pipeline and strategic decisions to strengthen its position in the market.

11.10.2024 - NVAX Stock was down 10.5%

• The green signal from the FDA for Novavax's COVID-19-influenza combo vaccine late-stage trial potentially boosted investor confidence.
• Concerns surrounding the upcoming Q3 earnings report, with anticipated negative earnings and uncertainties about exceeding expectations, likely triggered the sell-off of NVAX shares.
• Ongoing discussions with the FDA regarding the removal of the clinical hold on its vaccine programs may have introduced uncertainty into the stock's performance, influencing today's bearish trend.

11.10.2024 - NVAX Stock was down 6.2%

• Concerns may have arisen among investors about Novavax's ability to meet market expectations following the FDA's approval for the company's COVID-19-influenza combo vaccine late-stage trial.
• The bearish movement in NVAX's stock price could be attributed to the anticipation of negative earnings and uncertainties surrounding the company's upcoming report.
• A sell-off of NVAX shares in the market may be a result of investors' cautious approach towards the company's financial performance and its potential impact on stock value.

11.10.2024 - NVAX Stock was down 10.2%

• Despite receiving FDA approval for the late-stage trial of its COVID-19-influenza combination vaccine, Novavax (NVAX) observed a downturn in its stock performance today.
• Increased options trading activity and anticipation surrounding the upcoming third-quarter earnings announcement likely heightened volatility in the stock price.
• Investors might have had elevated hopes for positive updates regarding the FDA's removal of the clinical hold during the earnings call, resulting in disappointment and a negative market response.
• The company's stock faced downward pressure possibly due to the absence of favorable factors for a potential earnings surpass, as per recent analysis.

13.10.2024 - NVAX Stock was down 6.4%

• The company shared strong Q3 earnings and revenue figures, but the stock dropped 6% following a reduction in sales forecast due to lower COVID-19 vaccine demand.
• Despite the positive financial results, the stock was impacted by the revised sales guidance.
• The FDA's approval for Novavax's late-stage trial of a COVID-19-influenza combination vaccine could have a favorable long-term effect on the stock, but the current downward movement might be due to short-term worries regarding sales expectations.

08.00.2025 - NVAX Stock was down 9.3%

• The dip in NVAX stock today may be due to investors taking profits after a recent rise in share price.
• Despite optimistic reports on Novavax's vaccine development and recent share price increase, the absence of significant improvements in earnings estimate revisions may have prompted some investors to sell their holdings.
• The surge in vaccine stocks, including Novavax, in response to news of the first human death in the U.S. from the H5N1 bird flu virus and increased incidents of respiratory illnesses nationwide likely initially bolstered NVAX but could have led to profit-taking today.

12.10.2024 - NVAX Stock was down 5.8%

• The bearish movement in NVAX stock today could be attributed to the company reporting a Q3 loss despite topping revenue estimates, raising concerns about its profitability and financial health.
• The surge in options activity with a bullish approach from deep-pocketed investors may have initially boosted optimism, but the market sentiment might have shifted due to the reported loss.
• The FDA's green signal for Novavax's COVID-19-influenza combo vaccine late-stage trial could have been a positive catalyst, but investors might be waiting for more concrete updates on the clinical hold removal from the upcoming earnings call.
• The upcoming Q3 earnings report will be crucial for NVAX, as investors are eagerly awaiting management's updates on regulatory discussions and the company's overall performance, which could further influence the stock movement.

09.00.2025 - NVAX Stock was down 11.2%

• Novavax (NVAX) witnessed a significant 11.2% decrease in its shares amid a strong bearish movement today.
• Investor sentiment turned negative due to reports of the first human death in the U.S. linked to the H5N1 bird flu virus and information from a major health organization about the rise in respiratory illnesses. This caused volatility in the vaccine stock sector.
• While there was a noteworthy 13.5% surge in the share price recently following reports of a sharp uptick in respiratory illnesses by the aforementioned health organization, apprehensions stemming from the bird flu fatality dampened overall investor confidence, leading to the bearish sentiment.
• The conflicting information and uncertainties surrounding respiratory illnesses, as well as the progress in vaccine development, likely contributed to the stock's erratic performance and subsequent decline.